- ETX-636 preclinical data to be presented at the AACR annual meeting, showcasing superior potency and selectivity for all mutant forms of PI3Kα while sparing wildtype PI3Kα Mutant PI3Kα is a ...

First-in-human trial of ETX–636 to begin in Q2 2025 in patients with tumors harboring an activating PI3Kα mutation, including breast cancer - ETX-636 preclinical data to be presented at the ...